GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM102152
Query DataSets for GSM102152
Status
Public on Mar 30, 2006
Title
LS-83
Sample type
RNA
Source name
lung
Organism
Homo sapiens
Characteristics
Cancer
Extracted molecule
total RNA
Extraction protocol
Total RNA was isolated from lung squamous cell carcinoma samples according to Standard Trizol protocol.
Label
biotin
Label protocol
Approximately 5 µg of total RNA was processed to produce biotinylated cRNA targets.
Hybridization protocol
standard Affymetrix procedures
Scan protocol
standard Affymetrix procedures
Description
lung squamous carcinoma
Data processing
Affymetrix Microarray Suite version 5.0
Submission date
Mar 29, 2006
Last update date
Mar 29, 2006
Contact name
Jack Yu
E-mail(s)
[email protected]
Phone
858-320-3362
Fax
858-784-3182
Organization name
Veridex, LLC
Street address
3210 Merryfield Row
City
San Diego
State/province
CA
ZIP/Postal code
92121
Country
USA
Platform ID
GPL96
Series (1)
GSE4573
Gene expression signatures for predicting prognosis of squamous cell lung carcinomas
Data table header descriptions
ID_REF
VALUE
MAS5-calculated Signal intensity after global scaling the average intensity to 600.
Data table
ID_REF
VALUE
AFFX-BioB-5_at
1038.1
AFFX-BioB-M_at
1575.2
AFFX-BioB-3_at
832.7
AFFX-BioC-5_at
3466.1
AFFX-BioC-3_at
3421.6
AFFX-BioDn-5_at
5199.7
AFFX-BioDn-3_at
15657.2
AFFX-CreX-5_at
33957.3
AFFX-CreX-3_at
39970.1
AFFX-DapX-5_at
61.5
AFFX-DapX-M_at
103.3
AFFX-DapX-3_at
17.6
AFFX-LysX-5_at
22.1
AFFX-LysX-M_at
10.1
AFFX-LysX-3_at
33.6
AFFX-PheX-5_at
8.2
AFFX-PheX-M_at
11.3
AFFX-PheX-3_at
32
AFFX-ThrX-5_at
14.3
AFFX-ThrX-M_at
35.2
Total number of rows:
22283
Table truncated, full table size
363 Kbytes
.
Supplementary data files not provided
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|